Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Graefes Arch Clin Exp Ophthalmol ; 253(3): 457-65, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25500983

RESUMO

BACKGROUND: Recombinant human (rh) interferon alpha2a (IFN-α2a) therapy is successfully used for the treatment of Behçet's disease (BD) uveitis refractory to conventional immunosuppressive treatment. PURPOSE: Our aim in this study was to investigate the frequency and clinical significance of anti-IFN-α antibodies and autoantibodies during recombinant human rhIFN-α2a therapy in patients with BD uveitis. METHODS: This comparative, cross-sectional, serological screening study included 30 BD patients treated with rhIFN-α2a (Group 1), 29 BD patients treated with conventional immunosuppressive agents (Group 2), 29 BD patients who received only colchicine (Group 3), and 30 healthy subjects (Group 4). Anti-IFN-α-binding antibodies and autoantibodies, including anti-nuclear antibody, anti-thyroid peroxidase antibody, and anti-cardiolipin antibody, were measured in serum samples. Antibody seropositivity was compared between study groups. Retrospective clinical data were compared between antibody-positive and antibody-negative patients. RESULTS: A significantly higher proportion of patients in Group 1 had anti-interferon-α (26.6 %) and autoantibody (30 %) seropositivity compared to the other groups. No correlation was found between seropositivity for anti-interferon-α and other autoantibodies. No significant difference was found in cumulative dose of IFN-α, duration of IFN-α therapy, time to first uveitis attack, or attack rate between anti-interferon-α antibody-positive and antibody-negative patients in Group 1. Uveitis attacks were observed in 22 % of autoantibody-positive and 71 % of autoantibody-negative patients in Group 1 (p = 0.018). CONCLUSIONS: Patients with BD uveitis develop anti-IFN-α-binding antibodies and autoantibodies during treatment with rhIFN-α2a. While the clinical relevance of anti-IFN-α-binding antibodies remains unclear in this study, induction of autoimmunity was found to be associated with a tendency for better therapeutic response.


Assuntos
Anticorpos Anticardiolipina/sangue , Anticorpos Antinucleares/sangue , Autoanticorpos/sangue , Síndrome de Behçet/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Interferon-alfa/imunologia , Adulto , Síndrome de Behçet/imunologia , Colchicina/uso terapêutico , Estudos Transversais , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imunossupressores/uso terapêutico , Interferon alfa-2 , Interferon-alfa/uso terapêutico , Medições Luminescentes , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Adulto Jovem
2.
Doc Ophthalmol ; 128(2): 101-9, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24343574

RESUMO

PURPOSE: To assess structural or functional differences of the retina among subjects with persistent and resolved amblyopia. METHODS: Fourteen eyes with persistent amblyopia that did not reach normal visual acuity (VA) levels (≤0.1 LogMAR) despite amblyopia treatment, 18 eyes with resolved amblyopia, and 16 eyes of 16 normal subjects were included. All subjects underwent optical coherence tomography (OCT), pattern visual evoked potential (PVEP), and pattern electroretinography (PERG) evaluation. RESULTS: There was no significant difference in foveal thickness, foveal volume, macular volume, ganglion cell layer thickness, and total and sectorial retinal nerve fiber layer measurements among three groups (p > 0.05). Foveolar thickness was significantly increased in both resolved and persistent amblyopia groups compared with the control group (p = 0.031). However, there was no difference between amblyopic groups (p = 0.98). Although, in the PVEP study, N75 implicit time was found significantly prolonged in both amblyopia groups (p = 0.046), there were no significant differences in P100 implicit time and amplitude among the groups (p > 0.05). PERG amplitude of the persistent group was significantly lower than that of the control group (p = 0.003). There were no significant differences in P50, N95 implicit times among groups (p > 0.05). CONCLUSIONS: In our study, the only significant difference between persistent and resolved amblyopia groups was the initial VA. Neither OCT nor electrophysiological examinations were found to be useful in order to explain why some cases were resistant to the treatment for amblyopia.


Assuntos
Ambliopia/fisiopatologia , Potenciais Evocados Visuais/fisiologia , Retina/fisiopatologia , Acuidade Visual/fisiologia , Adolescente , Criança , Eletrorretinografia , Feminino , Humanos , Masculino , Erros de Refração/terapia , Estrabismo/cirurgia , Tomografia de Coerência Óptica
3.
Arq Bras Oftalmol ; 2023 Mar 24.
Artigo em Inglês | MEDLINE | ID: mdl-36995810

RESUMO

PURPOSES: To assess the efficacy of botulinum toxin A injection in the treatment of strabismus in patients with neurological impairment and evaluate the factors associated with treatment success. METHODS: The study included 50 patients with strabismus and neurological impairment. In all children, botulinum toxin injection was performed into the appropriate extraocular muscle. The relationship between demographic features, clinical characteristics, and treatment success were analyzed. RESULTS: In the study group, 34 patients had esotropia, and 16 patients had exotropia. As neurological problems, 36 patients had cerebral palsy, and 14 had hydrocephalus. The average follow-up period was 15.3 ± 7.3 months. The mean number of injections was 1.4 ± 0.6. The mean angle of deviation was 42.5 ± 13.2 PD before the treatment, which decreased to 12.8 ± 11.9 PD after the treatment. Successful motor alignment (orthotropia within 10 PD) was achieved in 60% of the patients. Binary logistic regression analysis revealed that esotropic misalignment and shorter duration of strabismus was significantly associated with treatment success in the study group. Patients with esotropia and lower angles of misalignment were more likely to be treated with a single injection. CONCLUSION: The use of botulinum toxin A for the treatment of strabismus in children with neurological impairment is a good alternative to conventional surgical therapy with a lower risk of overcorrection. The treatment outcome is better in esodeviations and shorter duration of strabismus, implying an advantage of early treatment.

4.
Arq. bras. oftalmol ; 87(4): e2021, 2024. tab
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1520240

RESUMO

ABSTRACT Purposes: To assess the efficacy of botulinum toxin A injection in the treatment of strabismus in patients with neurological impairment and evaluate the factors associated with treatment success. Methods: The study included 50 patients with strabismus and neurological impairment. In all children, botulinum toxin injection was performed into the appropriate extraocular muscle. The relationship between demographic features, clinical characteristics, and treatment success were analyzed. Results: In the study group, 34 patients had esotropia, and 16 patients had exotropia. As neurological problems, 36 patients had cerebral palsy, and 14 had hydrocephalus. The average follow-up period was 15.3 ± 7.3 months. The mean number of injections was 1.4 ± 0.6. The mean angle of deviation was 42.5 ± 13.2 PD before the treatment, which decreased to 12.8 ± 11.9 PD after the treatment. Successful motor alignment (orthotropia within 10 PD) was achieved in 60% of the patients. Binary logistic regression analysis revealed that esotropic misalignment and shorter duration of strabismus was significantly associated with treatment success in the study group. Patients with esotropia and lower angles of misalignment were more likely to be treated with a single injection. Conclusion: The use of botulinum toxin A for the treatment of strabismus in children with neurological impairment is a good alternative to conventional surgical therapy with a lower risk of overcorrection. The treatment outcome is better in esodeviations and shorter duration of strabismus, implying an advantage of early treatment.


RESUMO Objetivos: Avaliar a eficácia do uso de toxina bo-tulínica tipo A no tratamento do estrabismo em pacientes com comprometimento neurológico e avaliar os fatores associados ao sucesso do tratamento. Métodos: Cinquenta pacientes com estrabismo e comprometimento neurológico foram incluídos no estudo. Em todas as crianças, a toxina botulínica tipo A foi injetada no músculo extraocular apropriado. A relação entre características demográficas, características clínicas e o sucesso do tratamento foram analisadas. Resultados: No grupo de estudo, 34 pacientes tiveram esotropia e 16 pacientes tiveram exotropia, sendo trinta e seis pacientes com paralisia cerebral e 14 pacientes com hidrocefalia. O tempo médio de acompanhamento foi de 15,3 ± 7,3 meses. O número médio de aplicações foi de 1,4 ± 0,6. O ângulo de desvio médio foi de 42,5 ± 13,2 DP antes do tratamento e diminuiu para 12,8 ± 11,9 DP após o tratamento. Alinhamento motor bem sucedido (ortotropia dentro de 10 DP) foi alcançado em 60% dos pacientes. A análise de regressão logística binária revelou que o desalinhamento esotrópico e uma menor duração do estrabismo foram significativamente associados ao sucesso do tratamento no grupo de estudo. Pacientes esotrópicos com ângulos de desalinhamento menores são mais propensos a serem tratados com uma única aplicação. Conclusão: O uso da toxina botulínica tipo A para o tratamento de estrabismo em crianças com comprometimento neurológico é uma boa alternativa para a terapia cirúrgica convencional com menor risco de hipercorreção. O resultado do tratamento é melhor em exodesvios e em pacientes com estrabismo de menor duração, implicando em vantagem para o tratamento precoce.

5.
Curr Eye Res ; 40(6): 585-91, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25025864

RESUMO

PURPOSE: To evaluate the two-year follow-up of patients with type 1 retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) as adjunctive treatment. MATERIALS AND METHODS: We conducted a longitudinal follow-up study of premature infants who received 0.625 mg IVB therapy in addition to standard laser photocoagulation therapy. For comparison of the ophthalmological and neurological assessment outcomes of these infants, a control group was formed with 13 birth weight- and gestational age-matched infants who were treated with laser therapy alone for type 1 ROP. The neurological status of the study group and the control group was examined systematically, and neurodevelopmental evaluation was assessed by the Bayley Scales of Infant Development (BSID-III). RESULTS: A total of 18 eyes of 13 infants were included in the study. Anatomical success was obtained in 14 eyes (78%) and retinal detachment was observed in 4 eyes (22%). At two years of age, no significant difference was found in terms of spherical or cylindrical refractive errors compared to the control group. In control group, 2/13 patients' and in study group, 3/13 patients' neurological examinations were abnormal. No significant difference was found in the mean cognitive, language or motor BSID-III test scores of the groups. CONCLUSIONS: IVB appears to be useful for advanced ROP when laser treatment is precluded or not sufficient for preventing the progression of ROP. This pilot study indicates that IVB seems to contribute no further complications to the complications already present due to prematurity.


Assuntos
Bevacizumab/administração & dosagem , Desenvolvimento Infantil/fisiologia , Fotocoagulação a Laser/métodos , Retinopatia da Prematuridade/terapia , Inibidores da Angiogênese/administração & dosagem , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Injeções Intravítreas , Masculino , Projetos Piloto , Retinopatia da Prematuridade/diagnóstico , Fatores de Tempo , Resultado do Tratamento
6.
Curr Eye Res ; 38(7): 802-9, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23521720

RESUMO

PURPOSE: To investigate the morphological or functional differences of retina in amblyopia. MATERIALS AND METHODS: Forty-one patients with unilateral strabismic, anisometropic or combined amblyopia were included in the study. A control group was composed of 16 normal children. All participants were tested with optical coherence tomography (OCT) and pattern electroretinography (PERG). The findings from amblyopic and nonamblyopic eyes were compared among the amblyopic groups. Also, amblyopic and nonamblyopic eyes were compared with the healthy control eyes. RESULTS: No significant difference was found in OCT parameters for amblyopic and nonamblyopic eyes among the amblyopic groups (p > 0.05). In the combined and anisometropic groups, ganglion cell complex (GCC) was found to be significantly increased in both amblyopic and nonamblyopic eyes compared to the control group (p < 0.05). In strabismic amblyopia, significant reduction in GCC thickness and increase in foveal thickness were found, compared to nonamblyopic eyes (p = 0.019, p = 0.08). There were no significant differences in PERG amplitude and latency between the amblyopic and the nonamblyopic eyes in amblyopic groups (p > 0.05). PERG amplitude in amblyopic eyes was found to be significantly decreased compared with that in normal eyes (p < 0.05). When the nonamblyopic eyes were compared with the control group, only the anisometropic amblyopia group demonstrated significant reduction in amplitude and prolongation in latency (p = 0.002, p = 0.026). CONCLUSION: We found no significant differences in morphological and functional measures among amblyopic groups. However, we detected significant differences in the retinal function and morphology of both amblyopic and nonamblyopic eyes compared with healthy control eyes.


Assuntos
Ambliopia/fisiopatologia , Retina/fisiopatologia , Adolescente , Criança , Eletrorretinografia , Feminino , Humanos , Masculino , Fibras Nervosas/patologia , Células Ganglionares da Retina/patologia , Tomografia de Coerência Óptica , Acuidade Visual/fisiologia
7.
Br J Ophthalmol ; 97(1): 15-7, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23125061

RESUMO

PURPOSE: To collect data towards the establishment of a guideline to predict the population under risk for the development of retinopathy of prematurity (ROP) in Turkey. METHODS: Medical reports of 2950 preterm infants who underwent screening examinations for ROP between 1996 and 2010 at Istanbul Faculty of Medicine, Department of Ophthalmology were reviewed. The study population was classified as inpatient infants and referred infants. A risk factor analysis was performed limited to the 788 inpatient infants. The demographical variables regarding birth weight (BW), gestational age (GA) and postnatal age at the time of treatment were compared independently between 403 referred and 64 inpatient infants who were treated for severe ROP. RESULTS: The mean GA of the infants with severe ROP was 31.2±2.7 weeks, mean BW was 1543.4±508.3 g. The risk factor analysis of inpatient infants revealed BW<1500 g, GA<32 weeks; intraventricular haemorrhage, respiratory distress syndrome, sepsis, apnoea and phototherapy were associated with a higher incidence of ROP. In addition, sepsis, male gender, multiple gestations, BW<1500 g were associated with a higher incidence of progression to severe ROP, whereas maternal pre-eclampsia was associated with a lower incidence. On the other hand, comparison of demographic features revealed that the referred infants with ROP were born at a significantly higher BW and needed significantly earlier treatment than inpatient infants with ROP. CONCLUSIONS: The high BW and GA of infants with severe ROP indicate wider screening criteria should be used in our country. BW might be a more important criterion than GA for ROP screening.


Assuntos
Retinopatia da Prematuridade/epidemiologia , Peso ao Nascer , Progressão da Doença , Estudos Epidemiológicos , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Masculino , Guias de Prática Clínica como Assunto , Encaminhamento e Consulta , Retinopatia da Prematuridade/diagnóstico , Fatores de Risco , Turquia/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA